Nurix Therapeutics (NRIX) financial statements
Nurix Therapeutics reported revenue of $84M in fiscal 2025, up 18.0% a year over 6 years.
Net income was -$264M and the operating margin -340.2%, against -71.5% in 2019.
Free cash flow was -$263M.
The diluted share count rose 2532% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Nurix Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $31M | $18M | $30M | $39M | $77M | $55M | $84M |
| Research and development | $45M | $66M | $116M | $184M | $189M | $222M | $317M |
| Selling, general and admin | $8M | $16M | $31M | $38M | $43M | $46M | $53M |
| Operating income | -$22M | -$65M | -$118M | -$184M | -$155M | -$213M | -$286M |
| Pre-tax income | -$21M | -$64M | -$117M | -$180M | -$144M | -$193M | -$264M |
| Income tax | $239,000 | -$21M | $131,000 | $0 | $0 | $270,000 | $760,000 |
| Net income | -$22M | -$43M | -$117M | -$180M | -$144M | -$194M | -$264M |
| EPS (diluted) | -$6.59 | -$2.76 | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 |
| Diluted shares | 3M | 16M | 43M | 49M | 54M | 67M | 87M |
| Operating margin | -71.5% | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Net margin | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
Balance sheet
Fiscal years, from Nurix Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $38M | $281M | $296M | $309M | $288M | $610M | $593M |
| Receivables | — | — | $6M | $0 | — | $0 | — |
| Total current assets | $39M | $298M | $311M | $318M | $296M | $619M | $607M |
| Property, plant and equipment | $4M | $7M | $11M | $17M | $17M | $18M | $22M |
| Total assets | $44M | $396M | $477M | $417M | $356M | $669M | $688M |
| Total current liabilities | $16M | $45M | $66M | $71M | $87M | $96M | $86M |
| Total liabilities | $54M | $106M | $134M | $113M | $155M | $142M | $149M |
| Shareholders' equity | -$58M | $290M | $342M | $304M | $200M | $527M | $539M |
| Net debt | -$35M | -$119M | -$81M | -$64M | -$55M | -$110M | -$247M |
Cash flow
Fiscal years, from Nurix Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $601,000 | -$80,000 | -$84M | -$160M | -$81M | -$173M | -$249M |
| Capital spending | $2M | $5M | $6M | $12M | $8M | $9M | $14M |
| Free cash flow | -$1M | -$5M | -$90M | -$172M | -$90M | -$182M | -$263M |
| Stock-based compensation | $510,000 | $4M | $16M | $28M | $34M | $34M | $38M |
| Free cash flow margin | -3.4% | -26.0% | -302.6% | -445.4% | -116.6% | -333.4% | -313.7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NRIX.
Open NRIX in InvestinglyQuestions
What was Nurix Therapeutics's revenue in 2025?
$84M in fiscal 2025, from its 10-K filing.
How much free cash flow does Nurix Therapeutics generate?
-$263M in fiscal 2025 (operating cash flow minus capital spending).
From Nurix Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.